Picture of the author

Picture of the author

Value creation starts with a simple equation:

World-Leading Science + Entrepeneurs
= Value Creation

Our portfolio includes investments across all emerging disciplines, such as autonomous systems/AI, quantum technology, mobility, sustainable energy, genomics, synthetic biology, life sciences, and blockchain. This leads to a diversified portfolio of companies with category-creating potential.

Picture of the author

Picture of the author

Barrier Biosciences

Professor David Van Valen. AI-enabled drug discovery.

/

Picture of the author

Tera AI

Tony Zhang, PhD. Superhuman reasoning of the physical world.

Currently in stealth

Picture of the author

Receptive Bio

Professor Viviana Gradinaru. Neuroscience target discovery.

Currently in stealth

Picture of the author

3Laws Robotics

Professor Aaron Ames. Autonomous and robotic systems that do no harm.

/

Picture of the author

Palamedrix

Acquired by Somalogic (NASDAQ: SLGC). Intra-cellular interrogation at analyte resolution.

/

Picture of the author

ZeoDAC

Professor Mark Davis. Next-generation carbon capture and use.

/

Picture of the author

HEPT

Professor Ali Hajimiri. Hybrid electronic, photonic technology.

Currently in stealth

Picture of the author

Pinc

Professor Alireza Mirandi. Full spectrum, tunable, non-linear optics.

/

Picture of the author

Switch Therapeutics

Professor Bill Goddard. Next-generation RNAi therapies for unmet diseases.

/

Picture of the author

Soaring Technologies

Professor Mory Gharib. Drone technology for advanced military and logistics. American Made.

/

Picture of the author

Bohr QT

Professor Maria Spiropulu. Quantum networking at the speed of light.

/

Picture of the author

Flion

Professor Kimberly See. Sustainable energy storage from abundant eco-materials.

Currently in stealth

Picture of the author

Port Therapeutics

Professor Mikhail Shapiro. Ultrasound-enabled drug discovery.

Currently in stealth

Picture of the author

DNATwo

Professor J. Campbell & B. Stoltz. Novel cancer therapeutics targeting DNA repair and replication.

Currently in stealth